Overcoming Financial Toxicities of Cancer Care

Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

This breakthrough therapy designation of ziftomenib marks the first of its kinds in NPM1-mutant acute myeloid leukemia.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.

Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.